Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent Close of $42M Series D Financing
Published on 08/07/2025 at 18:05 | prnewswire.co.uk
Accomplished leader brings strong track record of commercial expansion in the US Company is focused on accelerating uptake of Phagenyx® to treat more patients in the US and EuropePhagenyx® is a first-of-its-kind therapy using neurostimulation to restore swallowing control in patients with severe swallowing difficulties (dysphagia)View original content:https://www.prnewswire.co.uk/news-releases/phagenesis-appoints-chad-hoskins-as-chief-executive-officer-following-recent-close-of-42m-series-d-financing-302239219.html
en | boerse | 67963571 |
